A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Inclusion Criteria:

• Gradual and progressive change in memory function reported by the participant orinformant for ≥6 months

• A MMSE score of 20 to 28 (inclusive) at Day 601 or 1.

• Meet flortaucipir F18 scan (central read) criteria

• Meet florbetapir F18 scan (central read) criteria

• Have a study partner who will provide written informed consent to participate, is infrequent contact with the participant (defined as at least 10 hours per week), andwill accompany the participant to the study or be available by telephone atdesignated times.

• A second study partner may serve as backup. The study partner(s) is/are required toaccompany the participant for signing consent. The study partner must be present onall days the cognitive and functional scales are administered.

• If a participant has a second study partner, it is preferred that 1 study partner beprimarily responsible for the CDR and the ADCS-ADL assessments.

• Days requiring the following assessments and scales must have a study partneravailable by telephone if not accompanying participant for the following assessments

• AEs and concomitant medications

• CDR, and

• ADCS-ADL

• Stable concomitant symptomatic AD medications and other medications that may impactcognition for at least approximately 30 days prior to randomization.

Exclusion Criteria:

• Has significant neurological disease affect the central nervous system other thanAD, that may affect cognition or ability to complete the study, including but notlimited to, other dementias, serious infection of the brain, Parkinson's disease,multiple concussions, or epilepsy or recurrent seizures (except febrile childhoodseizures).

• Has current serious or unstable illnesses including cardiovascular, hepatic, renal,gastroenterologic, respiratory, endocrinologic, neurologic (other than AD),psychiatric, immunologic, or hematologic disease and other conditions that, in theinvestigator's opinion, could interfere with the analyses in this study; or has alife expectancy of <24 months.

• History of cancer within the last 5 years, except of non-metastatic basal and/orsquamous cell carcinoma of the skin, in situ cervical cancer, nonprogressiveprostate cancer, or other cancers with low risk of recurrence or spread.

• Contraindication to MRI or PET scans